Protagenic Therapeutics - רווח החברה לפני מסים, ריבית ופחת PTIX

The base operating result before depreciation and amortization demonstrates stagnation, as the metric value stands at 0.00. This trend is driven by a lack of revenue and the critical dependence of Protagenic Therapeutics (PTIX) on grants. Stability is maintained through the outsourcing of peptide synthesis via certified US laboratories, while the scientific community maintains confidence in the company's innovative developments in depression therapy.

This metric reflects the net cash flow from operating activities before mandatory payments, allowing for an assessment of the business's actual ability to generate liquidity. By analyzing the EBITDA growth trajectory, an investor can identify the risk of resource depletion for Protagenic Therapeutics (PTIX), whose peptide clinical trial outsourcing model minimizes capital expenditures but creates a critical dependence on the payment discipline of external medical partners.